Jeehoon Ghil

825 total citations
23 papers, 618 citations indexed

About

Jeehoon Ghil is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Rheumatology. According to data from OpenAlex, Jeehoon Ghil has authored 23 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 14 papers in Pediatrics, Perinatology and Child Health and 11 papers in Rheumatology. Recurrent topics in Jeehoon Ghil's work include Biosimilars and Bioanalytical Methods (23 papers), Pharmaceutical studies and practices (14 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). Jeehoon Ghil is often cited by papers focused on Biosimilars and Bioanalytical Methods (23 papers), Pharmaceutical studies and practices (14 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). Jeehoon Ghil collaborates with scholars based in South Korea, United Kingdom and United States. Jeehoon Ghil's co-authors include Soo Yeon Cheong, Asta Baranauskaitė, Jiří Vencovský, Paul Emery, W. Porawska, Piotr Leszczyński, Agnieszka Zielińska, Michael E. Weinblatt, Artur Racewicz and Margarita Pileckytė and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

Jeehoon Ghil

21 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeehoon Ghil South Korea 9 546 287 259 219 82 23 618
Krystyna Jedrychowicz‐Rosiak South Korea 8 464 0.8× 190 0.7× 210 0.8× 180 0.8× 67 0.8× 10 525
W. Porawska Poland 9 499 0.9× 356 1.2× 209 0.8× 198 0.9× 124 1.5× 15 684
Jaroslaw Niebrzydowski South Korea 6 367 0.7× 148 0.5× 159 0.6× 147 0.7× 51 0.6× 8 410
Vladimir Kadinov Bulgaria 5 419 0.8× 191 0.7× 135 0.5× 148 0.7× 63 0.8× 6 453
Svitlana Smiyan Ukraine 6 373 0.7× 132 0.5× 146 0.6× 152 0.7× 57 0.7× 26 425
Edgar Ramiterre United States 5 694 1.3× 291 1.0× 227 0.9× 222 1.0× 136 1.7× 10 790
Mevludin Mekić Bosnia and Herzegovina 7 278 0.5× 119 0.4× 106 0.4× 108 0.5× 45 0.5× 26 359
Ivan Staykov Austria 5 264 0.5× 104 0.4× 106 0.4× 108 0.5× 39 0.5× 5 295
Jolanta Węgłowska Poland 6 336 0.6× 77 0.3× 109 0.4× 122 0.6× 27 0.3× 16 437
Johann Poetzl United Kingdom 8 299 0.5× 112 0.4× 128 0.5× 123 0.6× 46 0.6× 15 337

Countries citing papers authored by Jeehoon Ghil

Since Specialization
Citations

This map shows the geographic impact of Jeehoon Ghil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeehoon Ghil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeehoon Ghil more than expected).

Fields of papers citing papers by Jeehoon Ghil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeehoon Ghil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeehoon Ghil. The network helps show where Jeehoon Ghil may publish in the future.

Co-authorship network of co-authors of Jeehoon Ghil

This figure shows the co-authorship network connecting the top 25 collaborators of Jeehoon Ghil. A scholar is included among the top collaborators of Jeehoon Ghil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeehoon Ghil. Jeehoon Ghil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Joseph P., et al.. (2022). Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One. BioDrugs. 36(4). 431–436. 4 indexed citations
2.
Smolen, Josef S, Young Mo Kang, Wan‐Hee Yoo, et al.. (2020). Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Research & Therapy. 22(1). 188–188. 3 indexed citations
3.
Egeberg, Alexander, Giampiero Girolomoni, Steven R. Feldman, et al.. (2020). Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR).. Journal of Drugs in Dermatology. 19(3). 316–318. 4 indexed citations
4.
Smolen, Josef S, Jung‐Yoon Choe, Michael E. Weinblatt, et al.. (2020). Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open. 6(1). e001096–e001096. 4 indexed citations
5.
Gonçalves, João, et al.. (2019). SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therapeutic Advances in Gastroenterology. 12. 3973079945–3973079945. 8 indexed citations
6.
Ghil, Jeehoon, et al.. (2018). Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis. Current Medical Research and Opinion. 35(3). 497–502. 13 indexed citations
7.
Emery, Paul, Michael E. Weinblatt, Josef S Smolen, et al.. (2018). THU0184 Impact of immunogenicity on clinical efficacy and administration related reaction in tnf inhibitors: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 77. 310–311. 3 indexed citations
8.
Weinblatt, Michael E., Asta Baranauskaitė, Eva Dokoupilová, et al.. (2018). Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology. 70(6). 832–840. 101 indexed citations
9.
Emery, Paul, Jiří Vencovský, Piotr Leszczyński, et al.. (2017). Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Annals of the Rheumatic Diseases. 76(12). 1986–1991. 87 indexed citations
10.
11.
Emery, Paul, Jiří Vencovský, Piotr Leszczyński, et al.. (2017). 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Lara D. Veeken. 56(12). 2093–2101. 54 indexed citations
12.
13.
Weinblatt, Michael E., Asta Baranauskaitė, Jaroslaw Niebrzydowski, et al.. (2017). Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis. Arthritis & Rheumatology. 70(1). 40–48. 110 indexed citations
14.
15.
Ghil, Jeehoon, et al.. (2017). FRI0198 Usability and safety of SB5 (an adalimumab biosimilar) pre-filled syringe and pre-filled pen in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 76. 556–557. 2 indexed citations
16.
17.
18.
Emery, Paul, Jiří Vencovský, Piotr Leszczyński, et al.. (2016). THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4. Annals of the Rheumatic Diseases. 75. 236–236. 16 indexed citations
19.
Emery, Paul, Jiří Vencovský, Piotr Leszczyński, et al.. (2015). A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases. 76(1). 51–57. 174 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krystyna Jedrychowicz‐Rosiak Breakdown of academic impact, for papers by W. Porawska Breakdown of academic impact, for papers by Jaroslaw Niebrzydowski Breakdown of academic impact, for papers by Vladimir Kadinov Breakdown of academic impact, for papers by Svitlana Smiyan Breakdown of academic impact, for papers by Edgar Ramiterre Breakdown of academic impact, for papers by Mevludin Mekić Breakdown of academic impact, for papers by Ivan Staykov Breakdown of academic impact, for papers by Jolanta Węgłowska Breakdown of academic impact, for papers by Johann Poetzl
Rankless by CCL
2026